Why the study?
Recent neutral results from the CLEAR SYNERGY trial in acute myocardial infarction challenged previously reported benefits of colchicine from the LODOCO2 and COLCOT trials.
Does colchicine improve outcomes in patients with acute and chronic forms of coronary artery disease?
Does colchicine improve outcomes in patients with acute and chronic forms of coronary artery disease?
Low-dose colchicine may be beneficial in stable CAD but not in acute MI patients already receiving intensive pharmaco-invasive therapies.
Answers are grounded in this paper and cite their sources.
Caution against routine colchicine post-PCI in acute MI; leaves open its role and timing in stable CAD.
Colchicine is an anti-inflammatory drug for different inflammatory conditions and is approved for secondary prevention of cardiovascular events in patients with coronary artery disease, mainly based on the results of the LODOCO2 and COLCOT trials. The recently published CLEAR SYNERGY trial reported neutral results for colchicine in patients with acute myocardial infarction undergoing percutaneous coronary intervention, challenging the previous reported benefits of colchicine. While colchicine appeared rather safe across the different studies, the variation in efficacy may suggest that the one-size-fits-all for the treatment of acute and chronic forms of coronary artery disease may not be appropriate, and that low-dose colchicine may be beneficial as an add-on therapy in patients who are stable or recovering from acute event, and not so helpful in patients with acute myocardial infarction already receiving intensive pharmaco-invasive therapies.
No takes yet. Share an insight, caveat, or question.
Bonaventura et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: